Press release
Aprepitant Injection Market to Reach USD 1.31 Billion by 2034
Aprepitant Injection Market
The Global Aprepitant Injection Market is projected to grow from USD 610 million in 2024 to USD 1.31 billion by 2034, at a Compound Annual Growth Rate (CAGR) of 7.9% during the forecast period.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/59151
Key Highlights:
• 2024 Market Size: USD 610 Million
• 2034 Forecast: USD 1.31 Billion
• CAGR: 7.9% (2024-2034)
• Main Growth Drivers: Rising global cancer prevalence, increasing chemotherapy use, and expanding inclusion of aprepitant in clinical guidelines
• Challenges: High cost of branded injectables, limited access in low-income countries
• Top Companies: Heron Therapeutics, Dr. Reddy's Laboratories, Mylan N.V. (Viatris), Pfizer, Fresenius Kabi, Baxter International, Accord Healthcare, Glenmark, Cipla, Teva Pharmaceuticals
Segmentation Analysis
By Type:
• Emulsion Injection
• Lyophilized Powder for Injection
By Dosage:
• 40 mg
• 125 mg
• 150 mg
• Others
By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By End User:
• Hospitals
• Oncology Clinics
• Ambulatory Surgical Centers
Summary:
150 mg emulsion injections are commonly preferred for single-dose administration in combination regimens. Hospital pharmacies lead in distribution due to centralized oncology treatment. Oncology clinics are expanding their use of aprepitant injections for both inpatient and outpatient chemotherapy protocols.
Get Your Exclusive Offer with up to 10% Discount:
https://exactitudeconsultancy.com/purchase/?currency=USD&type=single_user_license&report_id=59151
Regional Analysis
North America:
• Largest market, primarily led by the U.S.
• High chemotherapy volumes, strong clinical adoption, and insurance coverage drive sustained use.
• Aprepitant (IV) is often used in combination with 5-HT3 antagonists and corticosteroids, as recommended by NCCN and ASCO guidelines.
Europe:
• Germany, France, the UK, and Italy are key adopters.
• Robust cancer screening programs and supportive drug reimbursement fuel consistent demand.
• Preference for injectable antiemetics in multi-drug oncology protocols.
Asia-Pacific:
• Fastest-growing region, with a projected CAGR above 9%.
• China and India show rising chemotherapy rates and improved access to supportive care.
• Government-led oncology treatment programs and broader awareness of CINV prevention are driving adoption.
Latin America:
• Brazil and Mexico lead the market with public hospital integration of CINV protocols.
• Improved access to generics has increased aprepitant usage in tertiary cancer centers.
Middle East & Africa:
• Gradual market growth with opportunities emerging in GCC countries and South Africa.
• Expansion of private cancer centers and specialty pharmacies supports market entry.
Summary:
While North America and Europe dominate in terms of revenue, Asia-Pacific represents the strongest growth potential, driven by rising cancer burdens, improving oncology infrastructure, and growing generic drug penetration.
Market Dynamics
Growth Drivers:
• Rising global cancer burden: Increasing incidence of breast, lung, colorectal, and hematologic cancers leads to higher chemotherapy rates.
• Expanded chemotherapy use: New drug combinations with high emetogenic potential increase the need for advanced antiemetics.
• Guideline-based adoption: Global oncology guidelines now recommend NK1 antagonists like aprepitant for moderate to highly emetogenic chemotherapy.
• Patient-centric care: Healthcare providers are prioritizing supportive therapies to improve overall treatment adherence and patient outcomes.
Key Challenges:
• High cost of branded aprepitant injectables: Cost remains a barrier in LMICs (low- and middle-income countries), though generics are easing the impact.
• Competing oral formulations: Aprepitant is also available in capsule form, which may be preferred in some outpatient or low-risk regimens.
• Cold chain logistics: Injectable formulations often require strict handling and storage, limiting reach in rural or under-equipped settings.
Emerging Trends:
• Generic and biosimilar expansion: Major players are introducing cost-effective injectable versions, increasing access globally.
• Fixed-dose combination injectables: Development of multi-drug injectable formulations to reduce dosing complexity.
• Tele-oncology and remote patient management: Growth in home-based chemotherapy and outpatient administration is influencing injectable usage patterns.
• Artificial intelligence in CINV prediction: Integration of AI tools for personalized antiemetic regimens may enhance clinical decisions.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/59151/global-aprepitant-injection-market
Competitive Landscape
Key Players:
• Heron Therapeutics - Known for Sustol® and Cinvanti®, leading IV aprepitant formulations in the U.S.
• Dr. Reddy's Laboratories - Offers generic aprepitant injection formulations across Asia, Europe, and Latin America.
• Pfizer - Among the earliest developers of aprepitant (brand name Emend®), now expanding with injectable forms.
• Mylan N.V. (Viatris) - Supplies affordable injectables in regulated and emerging markets.
• Fresenius Kabi - Global supplier of oncology support injectables with a focus on hospital and surgical centers.
• Baxter International - Known for sterile injectable solutions across therapeutic categories.
• Accord Healthcare - Actively expanding its injectable oncology support portfolio globally.
• Teva Pharmaceuticals - Broad injectable offerings with strong presence in hospital pharmacy channels.
• Cipla & Glenmark - Major Indian players offering injectable aprepitant across South Asia, Africa, and LATAM.
Competitive Summary:
The market is moderately consolidated, with innovators holding branded injectable rights and generics expanding access across emerging regions. Success depends on regulatory compliance, cost competitiveness, and hospital tender relationships.
Conclusion: Enhancing Chemotherapy Care with Proven Anti-Nausea Support
As the global oncology landscape becomes more complex, aprepitant injection offers clinicians a proven and effective tool to manage one of the most debilitating side effects of cancer therapy-nausea and vomiting. With its ability to prevent both acute and delayed CINV, aprepitant injections are increasingly being incorporated into standard oncology supportive care protocols.
This report is also available in the following languages : Japanese (アプレピタント注射剤), Korean (아프레피탄트 주사제), Chinese (阿瑞吡坦注射液), French (Injection d'aprépitant), German (Aprepitant-Injektion), and Italian (Iniezione di aprepitant), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/reports/59151/global-aprepitant-injection-market#request-a-sample
Our More Report:
Surface Mount Technology (SMT) Equipment
https://exactitudeconsultancy.com/reports/64453/global-surface-mount-technology-smt-equipment-market
Armoured Vehicles
https://exactitudeconsultancy.com/reports/64455/global-armoured-vehicles-market
Infant Car Seats
https://exactitudeconsultancy.com/reports/64457/global-infant-car-seats-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Aprepitant Injection Market to Reach USD 1.31 Billion by 2034 here
News-ID: 4124887 • Views: …
More Releases from Exactitiude Consultancy
Non-Muscle Invasive Bladder Cancer Market Industry Analysis by Size, Share, Grow …
Introduction
The Non-Muscle Invasive Bladder Cancer (NMIBC) market is poised for significant growth as advancements in intravesical therapies, immuno-oncology drugs, and molecular diagnostics improve patient outcomes. NMIBC, which accounts for about 70-75% of all newly diagnosed bladder cancer cases, is characterized by high recurrence rates but relatively low mortality compared to muscle-invasive forms. The rising global prevalence, particularly among aging populations, is prompting greater investment in early diagnosis, novel drug delivery…
NK Cell Therapy Market Size And Global Industry Forecast 2034
NK Cell Therapy Market Outlook 2024-2034: Immuno-Oncology Innovation and Off-the-Shelf Therapies Set the Stage for Rapid Growth
Introduction
The Natural Killer (NK) Cell Therapy market is one of the most dynamic segments in immuno-oncology, driven by breakthroughs in cell engineering, off-the-shelf allogeneic therapies, and combination regimens with checkpoint inhibitors. NK cells, part of the innate immune system, have demonstrated strong potential in targeting and destroying cancer cells without prior sensitization, making them…
Neuroendocrine Prostate Cancer Market Size, Share and Growth Report, 2034
Introduction
The Neuroendocrine Prostate Cancer (NEPC) market is emerging as a key focus area in oncology due to its aggressive nature, poor prognosis, and increasing recognition as a distinct clinical entity. NEPC can develop de novo or as a treatment-emergent form of advanced prostate cancer following androgen deprivation therapy (ADT) resistance. While rare, NEPC is challenging to treat, requiring a combination of chemotherapy, targeted agents, and investigational therapies. Rising awareness, advancements…
Metastatic Colorectal Cancer Market Size And Global Industry Forecast 2034
Introduction
The Metastatic Colorectal Cancer (mCRC) market is entering a transformative phase as precision medicine, biomarker-driven treatment strategies, and immunotherapy reshape patient care. Increasing adoption of EGFR inhibitors, VEGF inhibitors, immune checkpoint inhibitors, and combination regimens is improving survival rates, while advancements in molecular diagnostics are enabling more tailored treatment approaches. Over the next decade, continuous R&D efforts and expanded access to innovative therapies are expected to drive market growth.
Download Full…
More Releases for Aprepitant
Aprepitant API Market 2025: Industry Growth Forecast, Key Manufacturers, and Glo …
Los Angeles, United State: The global Aprepitant API market is comprehensive and accurately presented in the report with the help of detailed market information and data, critical findings, error-free statistics, and reliable forecasts. The report digs deep into important aspects of the global Aprepitant API market, including competition, segmentation, regional expansion, and market dynamics. Each leading trend of the global Aprepitant API market is carefully studied and elaborately presented in…
Aprepitant Market: Size, Share, Growth, Analysis, Key Players, Revenue, Growth | …
Global Aprepitant Market
Aprepitant is an antiemetic chemical compound that belongs to a class of drugs called substance P antagonists (SPA). It mediates its effect by blocking the neurokinin 1 (NK1) receptor.
The global Aprepitant market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered…
Aprepitant Market Analysis and Global Regional Outlook 2023-2030 | Merck & Co., …
Extensive analysis of the report "Aprepitant Market" is conducted by following key product positioning and monitoring the top competitors within the market framework by Infinitybusinessinsights.com. The report will assist reader with better understanding and decision making.
The Aprepitant market, closely linked to the pharmaceutical industry, encompasses the production and distribution of Aprepitant-based medications. Aprepitant, recognized for its effectiveness in managing chemotherapy-induced nausea and vomiting, finds application in cancer treatment and related…
Postoperative Nausea and Vomiting (PONV) Market to Register Sustainable Growth D …
DelveInsight's "Postoperative Nausea and Vomiting Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Postoperative Nausea and Vomiting Market Size and Share in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Postoperative Nausea and Vomiting (PONV) market report covers emerging drugs, treatment practices, market share of individual…
Aprepitant Market 2027: Industry Growth, Competitive Analysis & Future Prospects …
This report properly guides new entrants as well as established players to make a difference in the global Aprepitant market. It is just the right resource for any player looking to plan new strategies.
LOS ANGELES, United States: The report is an all-inclusive research study of the global Aprepitant market taking into account the growth factors, recent trends, developments, opportunities, and competitive landscape. The market analysts and researchers have done extensive…
Aprepitant Market Segmentation Along With Regional Outlook, Competitive Strategi …
Complete study of the global Aprepitant market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Aprepitant industry. Research techniques like PESTLE and Porter's Five Forces analysis have been deployed by the researchers. They have also provided accurate…
